结直肠癌风险位点与生存结局的综合分析:CDH1变异具有预后作用
该研究在1948例晚期结直肠癌患者中分析83个风险位点与生存的关系,发现CDH1的rs9939049与总生存显著相关,精细定位提示rs12597188亦与生存及治疗反应相关,提示CDH1变异或可作为预后生物标志物。
要点
- CDH1的rs9939049与晚期结直肠癌总生存显著相关(HR 1.44)。
- rs12597188与总生存相关且与治疗反应差相关。
- 通路内SNP组合未优于单个变异,其他风险SNP的荟萃分析无显著生存关联。
核心结论
- CDH1的结直肠癌易感SNP rs9939049影响患者生存,值得进一步评估作为预后生物标志物。
研究设计与样本
- 基于COIN和COIN-B临床试验的1948例无亲缘关系晚期结直肠癌患者,对83个风险位点直接基因分型10个、填补72个,采用Cox生存模型分析并设定Bonferroni阈值P=6.6×10-4。
主要发现
- 单变量分析发现6个SNP与总生存相关(P<0.05),仅CDH1的rs9939049超过Bonferroni阈值(HR 1.44,95%CI 1.21-1.71,P=5.0×10-5)。
- 精细定位显示rs12597188在该位点最显著,校正已知预后因素后仍显著(HR 1.23,95%CI 1.13-1.34,P=1.9×10-6)。
- rs12597188与治疗反应差相关(OR 0.61,95%CI 0.42-0.87,P=6.6×10-3)。
- 通路内SNP组合未较单个变异更显著关联生存,荟萃分析未发现其他风险SNP与生存相关。
临床怎么用
- CDH1的rs9939049和rs12597188或可作为晚期结直肠癌预后评估的候选标志物,但尚需进一步验证。
局限性
- 研究仅纳入晚期结直肠癌患者,结果外推需谨慎。
- 部分位点为填补数据,可能存在信息偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Genome-wide association studies have identified common single nucleotide polymorphisms (SNPs) at 83 loci associated with colorectal cancer (CRC) risk in European populations. Because germline variation can also influence patient outcome, we studied the relationship between these SNPs and CRC survivorship. EXPERIMENTAL DESIGN: For the 83 risk loci, 10 lead SNPs were directly genotyped, 72 were imputed and 1 was not genotyped nor imputed, in 1948 unrelated patients with advanced CRC from the clinical trials COIN and COIN-B (oxaliplatin and fluoropyrimidine chemotherapy ± cetuximab). A Cox survival model was used for each variant, and variants classified by pathway, adjusting for known prognostic factors. We imposed a Bonferroni threshold of P = 6.6 × 10-4 for multiple testing. We carried out meta-analyses of published risk SNPs associated with survival. RESULTS: Univariate analysis identified six SNPs associated with overall survival (OS) (P < 0.05); however, only rs9939049 in CDH1 remained significant beyond the Bonferroni threshold (Hazard Ratio [HR] 1.44, 95% Confidence Intervals [CI]: 1.21-1.71, P = 5.0 × 10-5). Fine mapping showed that rs12597188 was the most significant SNP at this locus and remained significant after adjustment for known prognostic factors beyond multiple testing thresholds (HR 1.23, 95% CI: 1.13-1.34, P = 1.9 × 10-6). rs12597188 was also associated with poor response to therapy (OR 0.61, 95% CI: 0.42-0.87, P = 6.6 × 10-3). No combinations of SNPs within pathways were more significantly associated with survival compared with single variants alone, and no other risk SNPs were associated with survival in meta-analyses. CONCLUSIONS: The CRC susceptibility SNP rs9939049 in CDH1 influences patient survival and warrants further evaluation as a prognostic biomarker.
引用
- Summers MG, Maughan TS, Kaplan R, et al. Comprehensive analysis of colorectal cancer-risk loci and survival outcome: A prognostic role for CDH1 variants. Eur J Cancer. 2019. PMID: 31734605. doi:10.1016/j.ejca.2019.09.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。